These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 31808835)

  • 41. Protocolized management of bleeding in hospitals in The Netherlands in patients treated with direct oral anticoagulants.
    Mitrovic D; Stapel L; Veeger N; Lameijer H; Meijer K; van Roon E
    Curr Med Res Opin; 2023 Jan; 39(1):71-79. PubMed ID: 36097788
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The Reversal of Direct Oral Anticoagulants in Animal Models.
    Honickel M; Akman N; Grottke O
    Shock; 2017 Aug; 48(2):144-158. PubMed ID: 28471371
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Developing a management plan for oral anticoagulant reversal.
    Dager WE
    Am J Health Syst Pharm; 2013 May; 70(10 Suppl 1):S21-31. PubMed ID: 23640529
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A review of oral anticoagulants, old and new, in major bleeding and the need for urgent surgery.
    Milling TJ; Ziebell CM
    Trends Cardiovasc Med; 2020 Feb; 30(2):86-90. PubMed ID: 30952383
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Management of major bleeding and outcomes in patients treated with direct oral anticoagulants: results from the START-Event registry.
    Testa S; Ageno W; Antonucci E; Morandini R; Beyer-Westendorf J; Paciaroni M; Righini M; Sivera P; Verhamme P; Pengo V; Poli D; Palareti G
    Intern Emerg Med; 2018 Oct; 13(7):1051-1058. PubMed ID: 29790125
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Review of the Pharmacology of the Emerging Possibilities of the Direct Oral Anticoagulants' Reversal.
    Samos M; Stanciakova L; Skornova I; Bolek T; Kovar F; Stasko J; Galajda P; Mokan M; Kubisz P
    Curr Drug Metab; 2017; 18(7):643-650. PubMed ID: 28412907
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Reversal of oral anticoagulation in patients with acute intracerebral hemorrhage.
    Kuramatsu JB; Sembill JA; Huttner HB
    Crit Care; 2019 Jun; 23(1):206. PubMed ID: 31171018
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Differential benefit risk assessment of DOACs in the treatment of venous thromboembolism: focus on dabigatran.
    Leung TS; Law EH
    Drug Des Devel Ther; 2015; 9():3557-69. PubMed ID: 26185422
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Emergency admissions for major haemorrhage associated with direct oral anticoagulants.
    Bouget J; Oger E
    Thromb Res; 2015 Dec; 136(6):1190-4. PubMed ID: 26545315
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Direct oral anticoagulants toxicity in children: an overview and practical guide.
    Daei M; Abbasi G; Khalili H; Heidari Z
    Expert Opin Drug Saf; 2022 Sep; 21(9):1183-1192. PubMed ID: 35924671
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Reversal of dabigatran-associated bleeding using idarucizumab: review of the current evidence.
    Giustozzi M; Verso M; Agnelli G; Becattini C
    J Thromb Thrombolysis; 2017 Nov; 44(4):527-535. PubMed ID: 28913672
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Current state of knowledge on oral anticoagulant reversal using procoagulant factors.
    Nitzki-George D; Wozniak I; Caprini JA
    Ann Pharmacother; 2013 Jun; 47(6):841-55. PubMed ID: 23695644
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Emergencies on direct oral anticoagulants: Management, outcomes, and laboratory effects of prothrombin complex concentrate.
    Bavalia R; Abdoellakhan R; Brinkman HJM; Brekelmans MPA; Hamulyák EN; Zuurveld M; Hutten BA; Westerweel PE; Olie RH; Ten Cate H; Kruip M; Middeldorp S; Meijer K; Coppens M
    Res Pract Thromb Haemost; 2020 May; 4(4):569-581. PubMed ID: 32548555
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Evaluation of definitions for oral anticoagulant-associated major bleeding: A population-based cohort study.
    Xu Y; Gomes T; Wells PS; Pequeno P; Johnson A; Sholzberg M
    Thromb Res; 2022 May; 213():57-64. PubMed ID: 35298939
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Direct Oral Anticoagulants in Cirrhosis Patients Pose Similar Risks of Bleeding When Compared to Traditional Anticoagulation.
    Intagliata NM; Henry ZH; Maitland H; Shah NL; Argo CK; Northup PG; Caldwell SH
    Dig Dis Sci; 2016 Jun; 61(6):1721-7. PubMed ID: 26725062
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Variation of renal function over time is associated with major bleeding in patients treated with direct oral anticoagulants for atrial fibrillation.
    Becattini C; Giustozzi M; Ranalli MG; Bogliari G; Cianella F; Verso M; Agnelli G; Vedovati MC
    J Thromb Haemost; 2018 May; 16(5):833-841. PubMed ID: 29460334
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Management Overview: Taking a Patient with Intracranial Hemorrhage Related to Direct Oral Anticoagulants to the Operating Room.
    Alturki A; Alamri A; Badawy M; Teitelbaum J
    World Neurosurg; 2016 Jun; 90():262-267. PubMed ID: 26960279
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Reversal Agents for the Direct Oral Anticoagulants.
    Ansell JE
    Hematol Oncol Clin North Am; 2016 Oct; 30(5):1085-98. PubMed ID: 27637309
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Bleeding complications from the direct oral anticoagulants.
    Sholzberg M; Pavenski K; Shehata N; Cserti-Gazdewich C; Lin Y
    BMC Hematol; 2015; 15():18. PubMed ID: 26705474
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Measurement and reversal of the direct oral anticoagulants.
    Samuelson BT; Cuker A
    Blood Rev; 2017 Jan; 31(1):77-84. PubMed ID: 27625113
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.